Express Pharma
Home  »  Latest Updates  »  Japan’s PMDA completes inspection of Lupin’s Mandideep facility (Unit-2)

Japan’s PMDA completes inspection of Lupin’s Mandideep facility (Unit-2)

21

The PMDA inspection closed with no critical or major observations

Pharma company Lupin today announced the completion of the Good Manufacturing Practices (GMP) inspection of its Mandideep facility (Unit-2), by the Pharmaceutical and Medical Devices Agency (PMDA), Japan. The inspection was conducted between May 14, 2019 and May 17, 2019.

The PMDA inspection closed with no critical or major observations.

Comments are closed.